Soreide K, Sandvik OM, Soreide JA, et al. Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46. https://doi.org/10.1016/j.canep.2015.10.031.

Article  PubMed  Google Scholar 

Serrano C, George S. Gastrointestinal stromal tumor: challenges and opportunities for a new decade. Clin Cancer Res. 2020;26:5078–85. https://doi.org/10.1158/1078-0432.CCR-20-1706.

Article  CAS  PubMed  Google Scholar 

DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–8. https://doi.org/10.1097/00000658-200001000-00008.

Article  CAS  PubMed  PubMed Central  Google Scholar 

von Mehren M, Kane JM, Bui MM, et al. NCCN guidelines insights: soft tissue sarcoma, Version 1.2021. J Natl Compr Cancer Netw. 2020;18:1604–12. https://doi.org/10.6004/jnccn.2020.0058.

Article  CAS  Google Scholar 

Casali PG, Blay JY, Abecassis N, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:20–33. https://doi.org/10.1016/j.annonc.2021.09.005.

Article  CAS  PubMed  Google Scholar 

Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265–72. https://doi.org/10.1001/jama.2012.347.

Article  CAS  PubMed  Google Scholar 

Wardelmann E, Thomas N, Merkelbach-Bruse S, et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol. 2005;6:249–51. https://doi.org/10.1016/S1470-2045(05)70097-8.

Article  CAS  PubMed  Google Scholar 

Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11:865–78. https://doi.org/10.1038/nrc3143.

Article  CAS  PubMed  Google Scholar 

Overholtzer M, Zhang J, Smolen GA, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA. 2006;103:12405–10. https://doi.org/10.1073/pnas.0605579103.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koo JH, Plouffe SW, Meng Z, et al. Induction of AP-1 by YAP/TAZ contributes to cell proliferation and organ growth. Genes Dev. 2020;34:72–86. https://doi.org/10.1101/gad.331546.119.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ou WB, Ni N, Zuo R, et al. Cyclin D1 is a mediator of gastrointestinal stromal tumor KIT-independence. Oncogene. 2019;38:6615–29. https://doi.org/10.1038/s41388-019-0894-3.

Article  CAS  PubMed  Google Scholar 

Song S, Honjo S, Jin J, et al. The Hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer. Clin Cancer Res. 2015;21:2580–90. https://doi.org/10.1158/1078-0432.CCR-14-2191.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Keren-Paz A, Emmanuel R, Samuels Y. YAP and the drug resistance highway. Nat Genet. 2015;47:193–4. https://doi.org/10.1038/ng.3228.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin L, Sabnis AJ, Chan E, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nat Genet. 2015;47:250–6. https://doi.org/10.1038/ng.3218.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen T, Ni N, Yuan L, et al. Proteasome inhibition suppresses KIT-independent gastrointestinal stromal tumors via targeting Hippo/YAP/cyclin D1 signaling. Front Pharmacol. 2021;12: 686874. https://doi.org/10.3389/fphar.2021.686874.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koepp DM, Schaefer LK, Ye X, et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science. 2001;294:173–7. https://doi.org/10.1126/science.1065203.

Article  CAS  PubMed  Google Scholar 

Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer. 2006;6:369–81. https://doi.org/10.1038/nrc1881.

Article  CAS  PubMed  Google Scholar 

Tu K, Yang W, Li C, et al. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol Cancer. 2014;13:110. https://doi.org/10.1186/1476-4598-13-110.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang J, Wang H, Peters M, et al. Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis. J Hepatol. 2019;71:742–52. https://doi.org/10.1016/j.jhep.2019.05.027.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang KK, Ramnarayanan K, Zhu F, et al. Genomic and epigenomic profiling of high-risk intestinal metaplasia reveals molecular determinants of progression to gastric cancer. Cancer Cell. 2018;33(137–50): e5. https://doi.org/10.1016/j.ccell.2017.11.018.

Article  CAS  Google Scholar 

Koga Y, Iwatsuki M, Yamashita K, et al. The role of FBXW7, a cell-cycle regulator, as a predictive marker of recurrence of gastrointestinal stromal tumors. Gastric Cancer. 2019;22:1100–8. https://doi.org/10.1007/s10120-019-00950-y.

Article  CAS  PubMed  Google Scholar 

Wu X, Iwatsuki M, Takaki M, et al. FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL1. Gastric Cancer. 2024;27:235–47. https://doi.org/10.1007/s10120-023-01454-6.

Article  CAS  PubMed  Google Scholar 

Teranishi R, Takahashi T, Obata Y, et al. Combination of pimitespib (TAS-116) with sunitinib is an effective therapy for imatinib-resistant gastrointestinal stromal tumors. Int J Cancer. 2023;152:2580–93. https://doi.org/10.1002/ijc.34461.

Article  CAS  PubMed  Google Scholar 

Therneau T. A package for survival analysis in S. R package version. 2015;2:2014.

Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466–78. https://doi.org/10.5858/2006-130-1466-GSTROM.

Article  CAS  PubMed  Google Scholar 

Blay JY, Perol D, Le Cesne A. Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors. Ann Oncol. 2012;23:1659–65. https://doi.org/10.1093/annonc/mdr622.

Article  PubMed  Google Scholar 

Azzolin L, Panciera T, Soligo S, et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell. 2014;158:157–70. https://doi.org/10.1016/j.cell.2014.06.013.

Article  CAS  PubMed  Google Scholar 

Park HW, Kim YC, Yu B, et al. Alternative Wnt signaling activates YAP/TAZ. Cell. 2015;162:780–94. https://doi.org/10.1016/j.cell.2015.07.013.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yu FX, Zhao B, Panupinthu N, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell. 2012;150:780–91. https://doi.org/10.1016/j.cell.2012.06.037.